| Q28214227 | Active site residues of cyclophilin A are crucial for its signaling activity via CD147 |
| Q77723474 | Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus |
| Q64379379 | Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice |
| Q44647021 | All- trans Retinoic Acid Modulates the Balance of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Patients With Emphysema * |
| Q46169786 | An electrophoretic method for the detection of chymotrypsin and trypsin activity directly in whole blood |
| Q31923131 | Angiogenesis: regulators and clinical applications |
| Q80576940 | Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus |
| Q62632545 | Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood |
| Q36985012 | Breast cancer progression: insights into multifaceted matrix metalloproteinases. |
| Q37207281 | Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice |
| Q37318152 | Cholinergic system during the progression of Alzheimer's disease: therapeutic implications |
| Q33981235 | Circulating levels of matrix proteases and their inhibitors in pregnant women with and without a history of recurrent pregnancy loss |
| Q91923336 | Clinical indicators and coronary angiographic features of expansive arterial remodelling in patients with abdominal aortic aneurysms |
| Q39900053 | Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure |
| Q33437197 | Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy |
| Q78747200 | Development of matrix metalloproteinase inhibitors in cancer therapy |
| Q48488515 | Differences of proteolytic enzymes and pathological changes in permissive and nonpermissive animal hosts for Angiostrongylus cantonensis infection |
| Q38019814 | EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis |
| Q42948386 | Effects of recombinant human endostatin and docetaxel on MMP and its following anti-neoplastic effect under different administration sequences |
| Q40713063 | Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma |
| Q47753186 | Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients |
| Q37464914 | Extracellular matrix fibrotic markers in heart failure |
| Q52322799 | Fluorescence Molecular Imaging and Tomography of Matrix Metalloproteinase-Activatable Near-Infrared Fluorescence Probe and Image-Guided Orthotopic Glioma Resection. |
| Q40566666 | Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases |
| Q37353175 | Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis |
| Q39141324 | Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion. |
| Q33576030 | Hypoxia, inflammation, and the tumor microenvironment in metastatic disease |
| Q33621874 | Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects |
| Q51696061 | Implications for matrix metalloproteinases as modulators of pediatric lung disease. |
| Q35892468 | Improving matrix metalloproteinase-2 specific response of a hydrogel system using electrophoresis. |
| Q33949202 | In vivo molecular target assessment of matrix metalloproteinase inhibition |
| Q33383620 | Increased expression of Matrix Metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein |
| Q73580710 | Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy |
| Q35829399 | Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats |
| Q39244267 | Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity. |
| Q38866279 | Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer |
| Q33277424 | Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma |
| Q33933063 | Matrix metalloproteinase biology applied to vitreoretinal disorders. |
| Q34798470 | Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke |
| Q73489754 | Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus |
| Q28140740 | Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis |
| Q37412311 | Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer |
| Q34616803 | Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. |
| Q35936620 | Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. |
| Q35107597 | Membrane type-matrix metalloproteinases (MT-MMP) |
| Q36129726 | Molecular optical imaging: applications leading to the development of present day therapeutics |
| Q91938288 | Nerve Growth Factor Pathobiology During the Progression of Alzheimer's Disease |
| Q35058554 | Niaspan attenuates the adverse effects of bone marrow stromal cell treatment of stroke in type one diabetic rats |
| Q30856771 | Novel 19F activatable probe for the detection of matrix metalloprotease-2 activity by MRI/MRS. |
| Q28366039 | Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients |
| Q45902395 | Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor-κB-dependent matrix metalloproteinase-9 expression. |
| Q39457461 | Phosphorylation of membrane type 1-matrix metalloproteinase (MT1-MMP) and its vesicle-associated membrane protein 7 (VAMP7)-dependent trafficking facilitate cell invasion and migration |
| Q35780997 | Photosensitizer-conjugated gold nanorods for enzyme-activatable fluorescence imaging and photodynamic therapy |
| Q37311888 | Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis |
| Q33325709 | Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis |
| Q53351916 | Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. |
| Q42972042 | Plasma levels of matrix metalloproteinase-8 in patients with carotid atherosclerosis. |
| Q53568806 | Plasma matrix metalloproteinase 2 levels and breast cancer risk. |
| Q30879183 | Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats |
| Q24798147 | Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in Type 2 diabetes |
| Q34122107 | Plasma membrane proteomics and its application in clinical cancer biomarker discovery |
| Q34096205 | Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases |
| Q78338951 | Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood |
| Q55456656 | Prediction of the anti-glioma therapeutic effects of temozolomide through in vivo molecular imaging of MMP expression. |
| Q36068428 | Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. |
| Q46021284 | Proteomic profiling identifies markers for inflammation-related tumor-fibroblast interaction. |
| Q33293388 | Reduced transthyretin expression in sera of lung cancer |
| Q82028412 | Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women |
| Q35769939 | Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection |
| Q36567357 | Role of matrix metalloproteinase-8 in atherosclerosis |
| Q92372937 | Role of the RAB7 Protein in Tumor Progression and Cisplatin Chemoresistance |
| Q39959867 | Role of the hemopexin domain of matrix metalloproteinases in cell migration |
| Q36081008 | Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients |
| Q80485496 | Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma |
| Q80274700 | Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma |
| Q44589894 | Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester |
| Q28285287 | Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer |
| Q41703683 | Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis |
| Q99571028 | The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity |
| Q35206514 | The increasing impact of laboratory medicine on clinical cardiology |
| Q51535970 | The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome. |
| Q41866398 | Tissue print of prostate biopsy: a novel tool in the diagnostic procedure of prostate cancer |
| Q48220254 | Topographically graded postischemic presence of metalloproteinases is inhibited by hypothermia |
| Q55035002 | Tumor-Derived Apoptotic Vesicles: With Death They Do Part. |
| Q79103460 | Use of plasma MMP‐2 and MMP‐9 levels as a surrogate for tumour expression in colorectal cancer patients |
| Q42440707 | Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients. |
| Q46433289 | Whole blood assay for trypsin activity using polyanionic focusing gel electrophoresis |
| Q39146647 | Zinc and metalloproteinases 2 and 9: What is their relation with breast cancer? |